RE: Leak?30 Sep 2025 12:25
Perhaps interest from the event which started on Sunday
Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce it will be attending the European Respiratory Society ("ERS") Congress commencing from 28 September 2025 in Amsterdam.
At the ERS Congress the Company will share new insights relating to its NXP002 lead programme - an inhaled treatment for idiopathic pulmonary fibrosis and related respiratory conditions. Following an in-depth pharmacology review, leveraging human and AI-methodologies, the pathways associated with disease progression in fibrotic diseases in which NXP002 has demonstrated both activity and clinical translation have been assessed across multiple organs.